-
Posted by
Two Blokes May 28 -
Filed in
Stock
-
1 view
Nothing attracts competition like the opportunity for profits, and the weight loss drug market has become arguably the healthcare industry's hottest opportunity in recent memory. Novo Nordisk (NVO 4.53%) has enjoyed tremendous success with semaglutide, the proprietary drug in Ozempic and Wegovy.
